Evidence map›Paper›PMID 28798687›Full record

ArticleFrontiers in pharmacology2017

TET2 Protects against oxLDL-Induced HUVEC Dysfunction by Upregulating the CSE/H

Juan Peng, Zhi-Han Tang, Zhong Ren, Bei He, Yun Zeng, Lu-Shan Liu, Zuo Wang, Dang-Heng Wei, Xi-Long Zheng, Zhi-Sheng Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Hydrogen Sulfide (HFrontiers in pharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Juan PengKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Zhi-Han TangKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Zhong RenKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Bei HeKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Yun ZengKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Lu-Shan LiuKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Zuo WangKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Dang-Heng WeiKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
Xi-Long ZhengDepartment of Biochemistry and Molecular Biology, Health Sciences Center, The Libin Cardiovascular Institute of Alberta, University of Calgary, CalgaryAB, Canada.
Zhi-Sheng JiangKey Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South ChinaHengyang, China.
University of South China · CNLibin Cardiovascular Institute of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ten-eleven translocation-2 (TET2) protein is a DNA demethylase that regulates gene expression through DNA demethylation and also plays important roles in various diseases including atherosclerosis. Endothelial dysfunction represents an early key event in atherosclerotic disease. The cystathionine-γ-lyase (CSE)/hydrogen sulfide (H

Indexed as

cystathionine-γ-lyase/hydrogen sulfideDNA demethylationendothelial dysfunctionoxidized low-density lipoproteinten-eleven translocation-2

Identifiers

PMID28798687
PMCPMC5526911
OpenAlexW2737522030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.